Jazz Pharmaceuticals plc
JAZZ
$167.10
$0.390.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.69% | 16.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.69% | 16.47% | |||
| Cost of Revenue | 10.85% | 55.56% | |||
| Gross Profit | 7.29% | 12.92% | |||
| SG&A Expenses | 5.79% | -30.27% | |||
| Depreciation & Amortization | 3.86% | 4.96% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.79% | -10.51% | |||
| Operating Income | 14.86% | 941.80% | |||
| Income Before Tax | 101.22% | -566.62% | |||
| Income Tax Expenses | -1,311.90% | 3.60% | |||
| Earnings from Continuing Operations | 134.99% | -676.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 134.99% | -676.38% | |||
| EBIT | 14.86% | 941.80% | |||
| EBITDA | 9.36% | 183.00% | |||
| EPS Basic | 135.28% | -673.65% | |||
| Normalized Basic EPS | 20.58% | 310.16% | |||
| EPS Diluted | 134.75% | -673.65% | |||
| Normalized Diluted EPS | 18.80% | 310.16% | |||
| Average Basic Shares Outstanding | -0.81% | 0.35% | |||
| Average Diluted Shares Outstanding | 0.67% | 0.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||